ASX / Media Release
5 December 2023

# Results of General Meeting

**Invex Therapeutics Ltd** (**Invex**, **ASX:IXC,** or **the Company**) today announces that in accordance with ASX Listing Rule 3.13.2 and in accordance with section 251AA(2) of the Corporations Act 2001, Invex advises the results of the General Meeting held virtually on Tuesday, 5 December at 1.00pm WST (Perth) time.

**RESOLUTION 1 – APPROVAL OF THE CAPITAL RETURN** was passed by way of a poll.

A copy of the proxy and poll results for this resolution is attached.

**- ENDS -**

*This release dated 5 December 2023 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.*

## For more information, please contact:

**Company/Investors**
Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

**Media**
Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

## About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

# Disclosure of Proxy Votes

**Invex Therapeutics Limited**

General Meeting

Tuesday, 05 December 2023

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes | | | | Poll Results (if applicable) | | | Results |
| | | | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 APPROVAL OF THE CAPITAL RETURN | P | 26,619,584 | 26,614,084 99.98% | 5,500 0.02% | 3,350,001 | 0 0.00% | 26,614,084 99.98% | 5,500 0.02% | 3,350,001 | Passed |